Emergent Biosolutions EBS Commercial Products — Total revenues
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's commercial products — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's commercial products — total revenues?
- Emergent Biosolutions (EBS) reported commercial products — total revenues of $42.9M in Q1 2026.
- How has Emergent Biosolutions's commercial products — total revenues changed year-over-year?
- Emergent Biosolutions's commercial products — total revenues decreased by 5.3% year-over-year, from $45.3M to $42.9M.
- What is the long-term trend for Emergent Biosolutions's commercial products — total revenues?
- Over 4 years (2021 to 2025), Emergent Biosolutions's commercial products — total revenues has grown at a -15.2% compound annual growth rate (CAGR), from $438M to $226.1M.
- What does commercial products — total revenues mean?
- Represents the total gross income generated from the sale of goods within the commercial products business segment. This metric reflects the market demand and pricing power for the company's non-government healthcare and public health offerings.